Recombinant Sendai Virus Vectors as Novel Vaccine Candidates Against Animal Viruses
Viruses · 21.05.2025 · 17 (5) · 737
DOI: 10.3390/v17050737 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 21.05.2025. Verfasst von Álex Gómez und 1 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Patología Animal, Universidad de Zaragoza, 177 Calle de Miguel Sevet, 50013 Zaragoza, Spain. Hauptthemen laut MEDLINE: Sendai virus, Viral Vaccines, Genetic Vectors, Virus Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gobierno de Navarra.
Abstract (Originalsprache)
Vaccination plays a pivotal role in the control and prevention of animal infectious diseases. However, no efficient and safe universal vaccines are currently registered for major pathogens such as influenza A virus, foot-and-mouth disease virus (FMDV), simian immunodeficiency virus (SIV), and small ruminant lentiviruses (SRLV). Here, we review the development of Sendai virus (SeV) vectors as a promising vaccine platform for animal diseases. Recombinant SeV vectors (rSeVv) possess several key features that make them highly suitable for developing vaccination strategies: (1) SeV has exclusively cytoplasmic replication cycle, therefore incapable of transforming host cells by integrating into the cellular genome, (2) rSeVv can accommodate large foreign gene/s inserts (~5 kb) with strong but adjustable transgene expression, (3) can be propagated to high titers in both embryonated chicken eggs and mammalian cell lines, (4) exhibits potent infectivity across a broad range of mammalian cells from different animals species, (5) undergo transient replication in the upper and lower respiratory tracts of non-natural hosts, (6) has not been associated with disease in pigs, non-humans primates, and small ruminants, ensuring a favorable safety profile, and (7) induce a robust innate and cellular immune responses. Preclinical and clinical studies using rSeVv-based vaccines against influenza A virus, FMDV, SIV, and SRLV have yielded promising results. Therefore, this review highlights the potential of rSeVv-based vaccine platforms as a valuable strategy for combating animal viruses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Patología Animal, Universidad de Zaragoza, 177 Calle de Miguel Sevet, 50013 Zaragoza, Spain.
- Instituto Agroalimentario de Aragón-IA2, Universidad de Zaragoza, 177 Calle de Miguel Sevet, 50013 Zaragoza, Spain.
- Instituto de Agrobiotecnología (CSIC-Gobierno de Navarra), 123 Avenida Pamplona, 31192 Mutilva, Spain.
ORCID-Profile: Álex Gómez, Ramsés Reina
Förderung
- Gobierno de Navarra
Zitieren
APA
Gómez, Á., & Reina, R. (2025). Recombinant Sendai Virus Vectors as Novel Vaccine Candidates Against Animal Viruses. Viruses, 17(5), 737. https://doi.org/10.3390/v17050737
Vancouver
Gómez Á, Reina R. Recombinant Sendai Virus Vectors as Novel Vaccine Candidates Against Animal Viruses. Viruses. 2025;17(5):737. doi:10.3390/v17050737
BibTeX
@article{Gmez2025,
author = {Gómez, Álex and Reina, Ramsés},
title = {Recombinant Sendai Virus Vectors as Novel Vaccine Candidates Against Animal Viruses},
journal = {Viruses},
year = {2025},
volume = {17},
number = {5},
pages = {737},
doi = {10.3390/v17050737}
}
EUVIMED